MedTrace Logo

A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

NCT06173076 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-08-27

No results posted yet for this study

Summary

Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases.

So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.

Conditions

  • Autoimmune Encephalitis
  • Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Sponsors & Collaborators

  • Shen Chun-Hong

    lead OTHER

Principal Investigators

  • Chun-Hong Shen · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-18
Primary Completion
2027-12-31
Completion
2032-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06173076 on ClinicalTrials.gov